ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Red Wine and Cognac on Coronary Circulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00330213
Recruitment Status : Completed
First Posted : May 26, 2006
Last Update Posted : May 26, 2006
Sponsor:
Collaborator:
University of Tampere
Information provided by:
University of Turku

Brief Summary:
Red wine consumption is associated with reduced cardiovascular disease mortality, and the cardioprotective properties may be partly related to its ability to improve endothelial function. The purpose of this study was to determine whether moderate doses of red wine, de-alcoholized red wine and cognac improve coronary flow reserve.

Condition or disease Intervention/treatment Phase
Healthy Behavioral: red wine and cognac consumption Not Applicable

Detailed Description:

Moderate consumption of red wine is associated with reduced coronary artery disease mortality. Cardioprotective effects of red wine may be partly related to its ability to improve endothelial function. Red wine increases endothelium-dependent flow-mediated dilatation of the brachial artery acutely after ingestion. Moreover, a heavy dose of red wine (ethanol 1.0 g/kg) has been shown to increase coronary flow reserve (CFR) as measured with transthoracic Doppler echocardiography. CFR depicts the relative increase of coronary blood flow in response to maximal myocardial hyperemia induced by adenosine. It is reduced in atherosclerosis and various conditions associated with the dysfunction of coronary microcirculation, such as diabetes and hypercholesterolemia.

Both ethanol and antioxidative polyphenols have been implicated in beneficial endothelial effects of red wine. However, their relative contributions remain uncertain in vivo. It has been suggested that red wine has stronger vasoactive properties than other alcohol beverages, and even de-alcoholized red wine may be sufficient to improve flow-mediated dilatation of the brachial artery. Cognac is also known to contain polyphenols, but its effects on coronary circulation have not been evaluated.

The purpose of this randomized controlled cross-over study was to determine with transthoracic echocardiography whether moderate doses of red wine improve CFR in response to adenosine in healthy humans. We also studied contributions of ethanol and antioxidants by comparing the effects of equal doses of alcoholic and de-alcoholized red wine, and cognac on the plasma antioxidant capacity and CFR.


Study Type : Interventional  (Clinical Trial)
Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Effects of Red Wine and Cognac on Coronary Circulation
Study Start Date : October 2004
Study Completion Date : April 2005



Primary Outcome Measures :
  1. coronary flow reserve
  2. plasma antioxidant capacity


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy males

Exclusion Criteria:

  • smoking, medication of any kind

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00330213


Locations
Finland
Dept. Clinical Physiology and Nuclear Medicine, Turku University Hospital
Turku, Finland, FIN-20520
Sponsors and Collaborators
University of Turku
University of Tampere
Investigators
Principal Investigator: Tuomas O Kiviniemi, MD Dept. Clinical Physiology and Nuclear Medicine, Turku University Hospital